Revenue segments as reported by the company.

Life Sciences and Applied Markets Group

Diagnostics and Genomics Group

Agilent CrossLab Group

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Agilent Technologies

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Agilent Technologies posts strong Q1 earnings, eyes PFAS testing and CRISPR expansion

Agilent Technologies delivered robust Q1 results, raised full-year guidance, and remains confident in its growth drivers. Despite challenges in the genomics market and uncertainties ahead, the company is strategically positioned to capitalize on opportunities and drive continued success.

Agilent reports strong Q2 earnings but revises down second-half forecast

Agilent Technologies delivered strong Q2 results but revised down second-half forecasts due to economic uncertainties. The company remains focused on driving margin expansion, cost efficiencies, and customer service excellence. Challenges from macroeconomic factors and market dynamics are being addressed with a strategic outlook for long-term growth.

Agilent Technologies faces China revenue challenges but eyes growth opportunities

Agilent Technologies faces revenue challenges in China but sees growth opportunities in companion diagnostics and liquid biopsy markets. The company remains confident in its ability to drive earnings growth despite recent setbacks.

Agilent reports mixed Q4 results, eyes steady recovery in 2024

Agilent Technologies reported mixed Q4 results with revenue decline but exceeded EPS guidance. While facing challenges in China and certain segments, the company anticipates slow but steady recovery for FY 2024. Agilent is focusing on cost-saving measures, pricing trends, and investments in growth areas like genomics and environmental solutions.

Agilent reports Q1 revenue decline, eyes global growth opportunities

Agilent Technologies' Q1 performance showed revenue decline but with strengths in certain segments like ACG and consumables. Challenges include revenue declines in DGG and LSAG impacting margins. Opportunities lie in global growth prospects and potential market surprises.

Agilent Technologies faces revenue decline but eyes growth opportunities ahead

Agilent Technologies navigated a challenging market in Q2 2024 with revenue declines across all end markets. The company remains focused on customer-centric strategies, cost optimization, and growth investments while addressing visibility challenges and exploring opportunities in high-growth segments.

Agilent reports Q3 earnings beat, eyes growth through acquisitions

Agilent Technologies delivered a solid performance in Q3 2024, exceeding earnings per share guidance and raising revenue and EPS midpoint guidance.
While facing revenue decline, the company's strategic investments and acquisitions signal a focus on growth and innovation.
Challenges include market dynamics and integration risks, but opportunities exist in leveraging digital initiatives and financial strength for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Agilent Technologies (A) expands the use of PD-L1 IHC 22C3 pharmDx assay for cancer treatment in the European Union.

Agilent (A) Expands pharmDX Assay Use in the European Union

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent to webcast fiscal third quarter financial results August 17.

Agilent to Webcast Third-Quarter Fiscal Year 2021 Financial Results Presentation

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the company's PD-L1 IHC 22C3 pharmDx assay is now labeled for expanded use in patients with non-small cell lung cancer (NSCLC) in the European Union. PD-L1 IHC 22C3 pharmDx can now be used as an aid in identifying NSCLC patients with tumor PD-L1 expression of Tumor Proportion Score (TPS) ≥ 50% for treatment with Libtayo® (cemiplimab). This announcement underscores Agilent's continuing commitment to th

Agilent PD-L1 IHC 22C3 pharmDx Expands CE-IVD mark in Non-small Cell Lung Cancer (NSCLC)

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the availability of an optimized and verified eMethod for PFAS Analysis in Water by LC/TQ for testing per- and polyfluoroalkyl substances (PFAS) in drinking and surface water using liquid chromatography and mass spectrometry. PFAS—known as ‘forever chemicals'—are a group of man-made chemicals that include PFOA, PFOS, GenX, and many others. PFAS have been manufactured and used in a variety of industries wor

Agilent Announces Optimized and Verified Method for Testing Over 100 PFAS Compounds

CHADDS FORD, Pa., July 13, 2021 /PRNewswire/ -- MOBILion Systems Inc. , a pioneer in fast, efficient, highresolution instrumentation for biomarker discovery, diagnostics and biotherapeutic drug characterization, today announced the close of a $60 million Series C financing round.

MOBILion Systems Inc. Announces $60 Million Series C Financing Round Led by D1

Does Agilent Technologies (A) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Agilent Technologies (A) a Strong Momentum Stock: Buy Now?

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the publication of a study carried out in partnership with Resolution Bioscience (a part of Agilent) and Dana-Farber Cancer Institute. The paper was published in the New England Journal of Medicine (NEJM) on June 24 and is titled "Acquired Resistance to KRAS G12C Inhibition in Cancer." It demonstrates the clinical utility of liquid biopsy techniques to detect resistance to targeted therapies, including inh

Resolution Bioscience (a part of Agilent) Investigated Acquired Resistance to KRAS G12C Inhibition

PHILADELPHIA & SANTA MONICA, Calif.--(BUSINESS WIRE)--Macquarie Asset Management (Macquarie) and Wilshire Advisors LLC (Wilshire) today announced that Delaware Wilshire Private Markets Fund (the Fund), a first-of-its-kind offering, is available for accredited investors, providing efficient access to an institutional-quality diversified private markets portfolio, including private equity, private credit, alternative yield, and private real assets. “The launch of Delaware Wilshire Private Markets

Macquarie Asset Management and Wilshire Expand Access to Private Market Investment Solutions for Accredited Investors with the Launch of Delaware Wilshire Private Markets Fund

Agilent (A) reported earnings 30 days ago. What's next for the stock?

Agilent (A) Up 10.5% Since Last Earnings Report: Can It Continue?

Agilent (A) expands its Bio Liquid Chromatography solutions portfolio with three new systems to fulfil the needs of biopharma industry.

Agilent (A) Expands Presence in LC Market With New Systems

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of three InfinityLab Bio LC systems specifically developed to meet the needs of the biopharma industry. The release is central to the Agilent portfolio of complete Bio LC solutions, featuring instruments, columns, and supplies that seamlessly integrate with Agilent OpenLab and MassHunter software, and CrossLab services to maximize efficiency in biopharma labs. The three new systems include the 1

Agilent Completes the InfinityLab Bio LC Portfolio

Agilent (A) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Surging Earnings Estimates Signal Upside for Agilent (A) Stock

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Stéphane Bayen has received an Agilent Thought Leader Award. Dr. Bayen is an Associate Professor in the Department of Food Science and Agricultural Chemistry at McGill University in Montreal, Quebec, Canada. The award will support Dr. Bayen's research contributions to analytical techniques and the development of reliable and robust workflows to identify honey authenticity using non-targeted chemical f

Agilent Presents Thought Leader Award to Dr. Stéphane Bayen

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a presentation by Memorial Sloan Kettering Cancer Center (MSK) at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO) to discuss the Resolution ctDx Lung, a laboratory-developed test (LDT) developed by Resolution Bioscience. The presentation titled Overall survival with circulating tumor DNA-guided therapy in advanced non-small cell lung cancer will present evidence for the clin

Cell-Free DNA Guided Targeted Therapy Leads to Better Survival in Advanced Non-Small Cell Lung Cancer

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the release of SureSelect Human All Exon V8 – a new exome design that provides comprehensive content and up-to-date coverage of protein coding regions from RefSeq, CCDS, and GENCODE. It also covers the TERT promoter and hard-to-capture exons that are omitted by other exomes on the market. The new design is available in three options – routine exome sequencing (Exome v8), clinical research sequencing (v8 Cl

Agilent Announces New SureSelect Human All Exon V8

Agilent has been a stealth value-creating play over the past years.

Agilent: Expensive, Yet Safe Bet

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Chris Elliott has received an Agilent Thought Leader Award. Dr. Elliott is Professor of Food Safety in the School of Biological Sciences and founder of the Institute for Global Food Security (IGFS) at Queen's University Belfast in Northern Ireland. The award recognizes his contributions to the field of food authenticity and the development of novel approaches to the detection of food fraud. Professor

Agilent Presents Thought Leader Award to Professor Chris Elliott

On the heels of a bang-up second quarter, Agilent Technologies Inc. (A) shares climbed more than 3% to $137.58 on Thursday. The Santa Clara, California-based provider of application-focused solutions to the life sciences, diagnostics and applied chemical markets has beaten earnings estimates in each of the past four quarters.

Agilent's 4th Consecutive Beat on Earnings Boosts Stock

Agilent's (A) fiscal second-quarter results benefit from strength across all geographical regions and end-market momentum.

Agilent (A) Q2 Earnings & Revenues Beat Estimates, Rise Y/Y

Analysts have provided the following ratings for Agilent Technologies (NYSE:A) within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 1 0 0 1 Somewhat Bullish 4 0 0 0 Indifferent 0 0 0 0 Somewhat Bearish 0 0 0 0 Bearish 0 0 0 0 In the last 3 months, 12 analysts have offered 12-month price targets for Agilent Technologies. The company has an average price target of $145.08 with a high of $160.00 and a low of $135.00.

What 12 Analyst Ratings Have To Say About Agilent Technologies

Agilent Technologies Inc. (A) CEO Mike McMullen on Q2 2021 Results - Earnings Call Transcript

Agilent (A) delivered earnings and revenue surprises of 18.29% and 9.91%, respectively, for the quarter ended April 2021. Do the numbers hold clues to what lies ahead for the stock?

Agilent Technologies (A) Q2 Earnings and Revenues Beat Estimates

Shares of Agilent Technologies (NYSE:A) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 36.62% over the past year to $0.97, which beat the estimate of $0.83.

Recap: Agilent Technologies Q2 Earnings

SANTA CLARA, Calif.--(BUSINESS WIRE)---- $A #Agilent--Agilent announces second quarter financial results; raises full-year guidance.

Agilent Reports Second-Quarter Fiscal Year 2021 Financial Results

Agilent Technologies (NYSE:A) unveils its next round of earnings this Tuesday, May 25. Here is Benzinga's everything-that-matters guide for the earnings announcement.

News for Agilent Technologies Stock (A)